This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).
Participants must have a diagnosis of relapsed or refractory Burkitt Lymphoma
Participants with Burkitt lymphoma must have relapsed or failed to respond to at least 1 prior line of multiagent chemoimmunotherapy with prior exposure to both an anti-CD20 antibody agent and an anthracycline.
No significant circulating disease, defined as an elevated total lymphocyte count above the upper limit of normal (ULN) due to the presence of malignant cells.
Participants with Burkitt Lymphoma must have Positron Emission Tomography (PET)-positive disease according to "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification"
Autologous transplant within 6 weeks of planned CAR-T cell infusion.
Recipient of prior CAR-T cell therapy targeting CD19 outside of this protocol.
Active other malignancy, other than non-melanoma skin cancer, carcinoma in situ (e.g., cervix, bladder, or breast).
Human immunodeficiency virus (HIV) seropositivity.
C. Babis Andreadis
Lead sponsor
University of California, San Francisco
Sponsor institution
University of California, Davis
Collaborator